A phase II trial of interleukin-2 and interferon Alfa-2a in patients with advanced renal cell carcinoma
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Renal Cell
In view of the minimal antitumor activity and associated toxicity, the combination of IL-2 and IFN-alpha in this trial cannot be recommended. The investigation of new cytokines and the identification of biologic prognostic factors for a response to immunologic therapy are essential.